TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30148803

Group type: EXPERIMENTAL
Intervention: Unilateral VEMP recording at 125 dB pe SPL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no VEMP testing)
Number of subjects: 60
Study: 28262598

Group type: EXPERIMENTAL
Intervention: AIMS (Adherence Improving self‐Management Strategy)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 221
Study: 25866384

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10 sessions before surgery
Number of subjects: 128

Group type: COMPARATOR
Intervention: Bariatric surgery alone
Number of subjects: 128
Study: 24225155

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy with electrons (21 Gy to the tumour bed during surgery)
Number of subjects: 1305

Group type: COMPARATOR
Intervention: External radiotherapy (50 Gy in 25 fractions of 2 Gy, followed by a boost of 10 Gy in five fractions)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy with electrons
Number of subjects: 1305

Group type: COMPARATOR
Intervention: External radiotherapy
Number of subjects: 1305
Study: 21207053

Group type: COMPARATOR
Intervention: Low-intensity resistance training with vascular restriction (LI-VRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-intensity resistance training (HI-RT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Exercise groups (LI-VRT and HI-RT)
Number of subjects: 37
Study: 19410624

Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel with CPG 7909 in saline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel with CPG 7909 at 0,2 month interval
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel with CPG 7909 at 0,1 month interval
Number of subjects: 24
Study: 17416113

Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg tablet from EMS Indústria Farmacêutica Ltda.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diamicron 80 mg tablet from Servier do Brazil Ltda. (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diamicron 80 mg tablet from Servier (Ireland) Industries Limited (Control)
Number of subjects: 0
Study: 15351936

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate (HRT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 32
Study: 11529341

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 142

Group type: COMPARATOR
Intervention: 5% hyperbaric lidocaine
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study: 9661037

Group type: EXPERIMENTAL
Intervention: Itraconazole solution (200 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole solution (200 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Capsule formulations (200 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All formulations (solution and capsules)
Number of subjects: 30
Study: 7845778

Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 21

Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 21
Study: 29848468

Group type: EXPERIMENTAL
Intervention: Eating4Two smartphone app
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 1330
Study: 27109158

Group type: EXPERIMENTAL
Intervention: Ganglioside (330g/day or 660g/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 25480020

Group type: EXPERIMENTAL
Intervention: High volume aerobic exercise (300 minutes/week)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Moderate volume aerobic exercise (150 minutes/week)
Number of subjects: 400
Study: 22891528

Group type: EXPERIMENTAL
Intervention: Health education intervention (lectures and focus group discussions)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no health education intervention)
Number of subjects: 320
Study: 21095399

Group type: EXPERIMENTAL
Intervention: Stock metal trays
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Directed-flow stock plastic trays
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stock plastic trays
Number of subjects: 7

Group type: COMPARATOR
Intervention: Custom trays with VPS impression materials
Number of subjects: 7
Study: 18834506

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 80
Study: 16948483

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC) 3 g/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 18
Study: 14753004

Group type: EXPERIMENTAL
Intervention: Electric sleep
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hofitol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electric sleep plus hofitol
Number of subjects: 90
Study: 10737699

Group type: EXPERIMENTAL
Intervention: 100 pg of androstadienone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 9366314

Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate
Number of subjects: 64
Study: 1489075

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with isobaric bupivacaine 0.5% at a dose of 0.5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia induced with thiopentone 2‐5 mg/kg, continued with low‐dose fentanyl (1‐2 micrograms/kg), oxygen/nitrous oxide/isoflurane (30/70/0.1‐0.5%), vecuronium
Number of subjects: 40
Study: 2860271

Group type: EXPERIMENTAL
Intervention: Intrapleural Corynebacterium parvum 7 mg
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 29526416

Group type: EXPERIMENTAL
Intervention: CMR-LGE quantification using a threshold of 8SD for peak TnI>50ng/mL
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CMR-LGE quantification using a threshold of 4SD for peak TnI>95ng/mL
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CMR-LGE quantification methods
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Correlation with peak troponin levels
Number of subjects: 93
Study: 28990590

Group type: EXPERIMENTAL
Intervention: Project Health
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 364

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 364
Study: 27403931

Group type: EXPERIMENTAL
Intervention: Glibenclamide (sulfonylurea)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Clinical model (baseline values of HbA1c and disposition index)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Glibenclamide + genetic markers
Number of subjects: 365
Study: 24739799

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Doxazosin 2 mg twice daily
Number of subjects: 15
Study: 22738096

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 76
Study: 20178952

Group type: EXPERIMENTAL
Intervention: Group recalling autobiographical episodes of conscientiousness and low openness to experience
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group recalling autobiographical episodes of low conscientiousness and high openness to experience
Number of subjects: 3
Study: 17673281

Group type: EXPERIMENTAL
Intervention: Presence of commercial PA facilities near homes
Number of subjects: 1556

Group type: COMPARATOR
Intervention: None (control group with no commercial PA facilities nearby)
Number of subjects: 1556
Study: 15829793

Group type: EXPERIMENTAL
Intervention: Shorter death to preservation time
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 1101
Study: 17039194

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study: 10206383

Group type: EXPERIMENTAL
Intervention: Sotalol (n=22)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Amiodarone (n=23)
Number of subjects: 75
Study: 7822649

Group type: EXPERIMENTAL
Intervention: Intraosseous injection system for delivering local anesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional delivery method of local anesthetic
Number of subjects: 0
Study: 1972008

Group type: EXPERIMENTAL
Intervention: dapiprazole 0.5% eye drops
Number of subjects: 50

Group type: COMPARATOR
Intervention: control eye (no dapiprazole)
Number of subjects: 50
Study: 287556

Group type: EXPERIMENTAL
Intervention: Adriamycin-DNA (ADR-DNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA (DNR-DNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracycline-DNA complexes
Number of subjects: 0
Study: 30763142

Group type: EXPERIMENTAL
Intervention: Darolutamide (600 mg [two 300-mg tablets] twice daily)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509
Study: 28569078

Group type: EXPERIMENTAL
Intervention: 20 μg/kg palonosetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 × 150 μg/kg ondansetron
Number of subjects: 0
Study: 25528694

Group type: EXPERIMENTAL
Intervention: Exposure to real chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined exposure and control groups
Number of subjects: 0
Study: 23017464

Group type: EXPERIMENTAL
Intervention: Savoury food items (e.g., mashed potatoes, tortilla chips)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Savoury food items (e.g., canned tomatoes, tortilla chips)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Savoury food items
Number of subjects: 15
Study: 21871095

Group type: EXPERIMENTAL
Intervention: Robotic arm therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study: 20053238

Group type: EXPERIMENTAL
Intervention: Intervention (Int) group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nonassessed Control (NAC) group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Assessed Control (AC) group
Number of subjects: 210
Study: 16460244

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Subpedicle connective tissue graft (CTG)
Number of subjects: 65
Study: 15369206

Group type: EXPERIMENTAL
Intervention: Motivational activities developed by the authors (enhanced condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control condition)
Number of subjects: 0
Study: 11138831

Group type: EXPERIMENTAL
Intervention: High Dk/t hydrogel lenses on a 30‐night EW schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Dk/t hydrogel lenses on a 6‐night EW schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfer to high Dk/t lenses after 12 months
Number of subjects: 0
Study: 9124993

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) monotherapy, daily dose of 12/1.5 g for an average of 10 days
Number of subjects: 33
Study: 8354894

Group type: EXPERIMENTAL
Intervention: Interleukin-1 alpha (IL-1 alpha) infusion
Number of subjects: 0
Study: 3730024

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (500-mg gelatine capsules) at 1 g/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (500-mg gelatine capsules) at 2 g/m2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous ifosfamide (Holoxan) at 1 g/m2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous ifosfamide (Holoxan) at 2 g/m2
Number of subjects: 18
Study: 30891654

Group type: EXPERIMENTAL
Intervention: ICD with ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICD with standard medical therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catheter ablation as primary therapy (registry cohort)
Number of subjects: 0
Study: 30583926

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery for distraction osteogenesis in M2A type mandible
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery for distraction osteogenesis in M2B type mandible
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery for distraction osteogenesis in M3 type mandible
Number of subjects: 40
Study: 28570481

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (specifics not provided)
Number of subjects: 290
Study: 25992488

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indapamide (1 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eplerenone and Indapamide
Number of subjects: 20
Study: 23084000

Group type: EXPERIMENTAL
Intervention: Diet with DCAD of -300 mEq/kg DM
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet with DCAD of 50 mEq/kg DM + 25(OH)D (3 mg/steer per day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet with DCAD of 150 mEq/kg DM + 25(OH)D (3 mg/steer per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diets with DCADs of 50 to 250 mEq/kg DM without 25(OH)D
Number of subjects: 6
Study: 21788266

Group type: EXPERIMENTAL
Intervention: Physiotherapy based on the Bobath concept, including one hour of structured task practice.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Structured task practice alone.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (Bobath and task practice)
Number of subjects: 26
Study: 19288251

Group type: EXPERIMENTAL
Intervention: SM(mod) - modified stapled mucosectomy (ligation and cutting of residual haemorrhoids)
Number of subjects: 45

Group type: COMPARATOR
Intervention: SM(std) - standard stapled mucosectomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SM(mod) - modified stapled mucosectomy
Number of subjects: 45
Study: 16960515

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 15515745

Group type: EXPERIMENTAL
Intervention: Thyroid hormone (thyroxine) replacement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hypothyroidic condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unchanged group (no thyroxine treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study: 11318050

Group type: EXPERIMENTAL
Intervention: Impeded parafoveal processing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal parafoveal processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct monitoring of eye movements
Number of subjects: 0
Study: 9241335

Group type: EXPERIMENTAL
Intervention: DBS3,3
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DBS3,2
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Modified DBS
Number of subjects: 45
Study: 7948054

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Psychotropic drug use
Number of subjects: 1628
Study: 2904827

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31926085

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in children
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Amoxicillin prescription in children
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Amoxicillin prescription in adults
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prescription in adults
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Ciprofloxacin prescription in children
Number of subjects: 1348
Study: 29635499

Group type: EXPERIMENTAL
Intervention: AA‐ORS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G‐ORS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SpD
Number of subjects: 40

Group type: COMPARATOR
Intervention: water
Number of subjects: 40
Study: 28192629

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (960 mg twice daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 170
Study: 26319384

Group type: EXPERIMENTAL
Intervention: Gastric balloon intervention for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (18 healthy volunteers)
Number of subjects: 18
Study: 23514100

Group type: EXPERIMENTAL
Intervention: Families for Health V2
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 21558586

Group type: EXPERIMENTAL
Intervention: Wearing red
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing an opponent in red
Number of subjects: 0
Study: 19290549

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Proton Pump Inhibitors
Number of subjects: 7
Study: 16702367

Group type: EXPERIMENTAL
Intervention: Current cigarette use
Number of subjects: 4383

Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day, smoking duration, and pack‐years
Number of subjects: 4383
Study: 15232813

Group type: COMPARATOR
Intervention: Intercostal nerve block plus IV PCA morphine (G1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine and fentanyl PCA infusion (G2)
Number of subjects: 31
Study: 11422533

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide-laurocapram (TNX)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TN)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vehicle control formulation (AN)
Number of subjects: 150
Study: 8996133

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg twice daily) with dexamethasone (8 mg twice on days 2 and 3, and 4 mg twice on day 4)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Metoclopramide (20 mg every 6 hours) with dexamethasone (8 mg twice on days 2 and 3, and 4 mg twice on day 4)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg twice daily) with dexamethasone
Number of subjects: 322

Group type: COMPARATOR
Intervention: Metoclopramide (20 mg every 6 hours) with dexamethasone
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg twice daily) in patients who vomited in the first 24 hours
Number of subjects: 322

Group type: COMPARATOR
Intervention: Metoclopramide (20 mg every 6 hours) in patients who vomited in the first 24 hours
Number of subjects: 322
Study: 8488369

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2906696

Group type: EXPERIMENTAL
Intervention: Intrarenal infusion of an alpha 1‐antagonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockade of alpha 2‐receptors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha 2‐receptors
Number of subjects: 0
Study: 29135728

Group type: EXPERIMENTAL
Intervention: Internal distraction device
Number of subjects: 64

Group type: COMPARATOR
Intervention: External distraction device
Number of subjects: 64
Study: 27522871

Group type: EXPERIMENTAL
Intervention: Hair analysis for Cannabis
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Hair analysis for Street Opioids
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Hair analysis for Cocaine
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Hair analysis for Prescribed Opioids
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Self-reported drug use (TLFB)
Number of subjects: 1285
Study: 24399455

Group type: EXPERIMENTAL
Intervention: Magnetic field therapy (2 Hz) applied to each hip region for 20 min, n = 35
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo magnetic field therapy applied to each hip region for 20 min, n = 31
Number of subjects: 66
Study: 24074502

Group type: EXPERIMENTAL
Intervention: Dexamethasone 30 mg perioperatively
Number of subjects: 41

Group type: COMPARATOR
Intervention: No dexamethasone
Number of subjects: 41
Study: 20870234

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 18853973

Group type: EXPERIMENTAL
Intervention: Adalimumab maintenance therapy (40 mg every other week)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Adalimumab maintenance therapy (40 mg weekly)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo after induction therapy
Number of subjects: 499
Study: 21063671

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 362

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 362
Study: 15994121

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation therapy combined with sertraline (LPSD group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sertraline monotherapy (Control group)
Number of subjects: 24
Study: 12448241

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate single-dose regimen
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate 5-day regimen
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cefazolin single-dose regimen
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cefazolin 5-day regimen
Number of subjects: 140
Study: 9609271

Group type: EXPERIMENTAL
Intervention: Low sodium diet (< or = 50 mmol sodium/day)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 361
Study: 7611580

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.15 mg/kg and 0.1 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion
Number of subjects: 36
Study: 2794058

Group type: EXPERIMENTAL
Intervention: MK-329 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14982

Group type: EXPERIMENTAL
Intervention: Flunisolide (active drug)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 50
Study: 11680667

Group type: COMPARATOR
Intervention: 5 ng/kg/min Ang II
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.5 ng/kg/min Ang II
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 ng/kg/min Ang II
Number of subjects: 9